Pharmacogenomics of opioids: an investigation of the genetic determinants of variability in analgesic response to opioids
| ISRCTN | ISRCTN35444083 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN35444083 |
| Protocol serial number | N0258123628 |
| Sponsor | Department of Health |
| Funder | The Royal Marsden NHS Trust |
- Submission date
- 30/09/2004
- Registration date
- 30/09/2004
- Last edited
- 19/10/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Signs and Symptoms
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Julia Riley
Scientific
Scientific
Palliative Care
Royal Marsden NHS Trust
Fulham Road
Chelsea
London
SW3 6JJ
United Kingdom
| Phone | +44 (0)20 7352 8171 |
|---|---|
| Julia.Riley@rmh.nhs.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Scientific title | Pharmacogenomics of opioids: an investigation of the genetic determinants of variability in analgesic response to opioids |
| Study objectives | The primary aim of this research project is to test the hypothesis that inter-subject variability in response to morphine is determined by polymorphisms in the u-opioid receptor gene. |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Analgesic response to opioids |
| Intervention | Randomised, blinded (Phase 2). Each subject will act as their own control. On visit one, subjects will be randomised to receive either intravenous morphine or intravenous saline (placebo). They will then cross-over to receive placebo or morphine respectively at the second visit. |
| Intervention type | Other |
| Primary outcome measure(s) |
Not provided at time of registration |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 01/10/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target sample size at registration | 100 |
| Key inclusion criteria | Total number RMH patients 100 |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 01/10/2003 |
| Date of final enrolment | 01/10/2005 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Palliative Care
London
SW3 6JJ
United Kingdom
SW3 6JJ
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Editorial Notes
19/10/2016: No publications found in PubMed, verifying study status with principal investigator.
